Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) insider Todd Alfred Carter sold 10,500 shares of Voyager Therapeutics stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $8.16, for a total value of $85,680.00. Following the completion of the transaction, the insider now owns 54,360 shares of the company’s stock, valued at approximately $443,577.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Todd Alfred Carter also recently made the following trade(s):
- On Thursday, July 6th, Todd Alfred Carter sold 5,500 shares of Voyager Therapeutics stock. The shares were sold at an average price of $10.80, for a total transaction of $59,400.00.
Voyager Therapeutics Trading Up 2.4 %
Shares of NASDAQ VYGR traded up $0.19 during trading hours on Monday, reaching $8.15. The stock had a trading volume of 275,681 shares, compared to its average volume of 465,678. The firm has a 50-day moving average of $9.29 and a 200-day moving average of $9.59. The firm has a market cap of $357.79 million, a price-to-earnings ratio of 3.51 and a beta of 1.03. Voyager Therapeutics, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $14.34.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on VYGR. Oppenheimer reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Voyager Therapeutics in a report on Monday, August 7th. StockNews.com assumed coverage on shares of Voyager Therapeutics in a report on Thursday, August 17th. They issued a “hold” rating for the company.
Institutional Trading of Voyager Therapeutics
Large investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new position in Voyager Therapeutics in the second quarter valued at $121,000. Nuveen Asset Management LLC acquired a new position in Voyager Therapeutics in the 2nd quarter valued at about $1,012,000. Alliancebernstein L.P. purchased a new stake in Voyager Therapeutics during the 2nd quarter valued at approximately $220,000. Wells Fargo & Company MN lifted its position in Voyager Therapeutics by 624.2% during the 2nd quarter. Wells Fargo & Company MN now owns 14,962 shares of the company’s stock worth $171,000 after acquiring an additional 12,896 shares during the period. Finally, Vestcor Inc purchased a new position in shares of Voyager Therapeutics in the 2nd quarter valued at approximately $437,000. Institutional investors and hedge funds own 58.81% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease.
- Five stocks we like better than Voyager Therapeutics
- What is a Non-Fungible Token (NFT)? Definition and How it Works
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- How to Invest in Social Media
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Which Wall Street Analysts are the Most Accurate?
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.